The September 2019 print issue of Bloomberg Businessweek featured a cover story titled “Can You Trust Generics?”, an in-depth 8-page investigation into the safety of the U.S. generic drug supply.

The article spotlights the discovery of N-Nitrosodimethylamine (NDMA)—a probable human carcinogen—in batches of commonly used generic drugs, including those tested by Valisure. With 90% of U.S. prescriptions filled by generics, the story raises a critical question:

“Valsartan is just the one we caught. Who knows how many more are out there?”

The piece was also adapted for online publication under the title: “Carcinogens Have Infiltrated the Generic Drug Supply in the U.S.”

Read the full article on Bloomberg here.

‍

The September 2019 print issue of Bloomberg Businessweek featured a cover story titled “Can You Trust Generics?”, an in-depth 8-page investigation into the safety of the U.S. generic drug supply.

The article spotlights the discovery of N-Nitrosodimethylamine (NDMA)—a probable human carcinogen—in batches of commonly used generic drugs, including those tested by Valisure. With 90% of U.S. prescriptions filled by generics, the story raises a critical question:

“Valsartan is just the one we caught. Who knows how many more are out there?”

The piece was also adapted for online publication under the title: “Carcinogens Have Infiltrated the Generic Drug Supply in the U.S.”

Read the full article on Bloomberg here.

‍